Gonorrhea Is Evolving Like Never Before.. In Michigan

24-year-old KC arrives at the ER with nuchal rigidity, photophobia, confusion, and difficulty speaking. Initial tests suggest bacterial meningitis, but her neurological symptoms point to meningoencephalitis, indicating a brain infection. Despite extensive testing, no common bacteria or viruses are identified, leaving doctors puzzled.

A diligent resident recalls the recent case of JW, a 66-year-old woman with unexplained, severe, and rapidly progressing joint pain, eventually diagnosed as disseminated gonococcal infection. This connection leads the resident to consider gonorrhea as a possible cause for KC's baffling symptoms, especially given her earlier, unexplained joint pain.

Further testing of KC's CSF confirms the presence of Neisseria gonorrhoeae, revealing she has gonococcal meningoencephalitis. KC's brief moment of clarity allows her to explain that her boyfriend had recently had chlamydia, and later, gonorrhea, explaining how she contracted the infection.

Public health officials in Michigan had been tracking a cluster of disseminated gonococcal infections since 2019. Genome sequencing of samples from affected patients, including KC and JW, revealed an identical strain of Neisseria gonorrhoeae, indicating a new, highly virulent strain capable of systemic spread was circulating.

The video provides a historical overview of Neisseria gonorrhoeae's alarming evolution of antibiotic resistance, from sulfanilamide in the 1930s, to penicillin in the 1940s, tetracycline in the 1950s, fluoroquinolones in the 1980s, and azithromycin in the 1990s. This continuous adaptation has left only one remaining effective antibiotic, ceftriaxone.

Analysis of the Michigan strain revealed a specific gene mutation, PorB1A, that created a protein enabling the bacteria to spread throughout the body, causing disseminated infections like septic arthritis and meningitis. This mutation increased the risk of dissemination by 20 times compared to other strains.

KC's condition improved with ceftriaxone treatment, leading to a full recovery. While the PorB1A strain has not been in circulation since 2023, concerns remain about the potential for Neisseria gonorrhoeae to evolve resistance to ceftriaxone, especially with its enhanced ability to disseminate, leading to a 'multidrug resistant super gonorrhea'.